Acadia Healthcare (NASDAQ:ACHC) Stock Rating Lowered by StockNews.com

Acadia Healthcare (NASDAQ:ACHC) was downgraded by equities researchers at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Friday.

Several other research analysts also recently commented on the company. TD Cowen boosted their target price on Acadia Healthcare from $86.00 to $101.00 and gave the stock an “outperform” rating in a report on Friday, March 1st. Barclays reduced their price objective on Acadia Healthcare from $100.00 to $91.00 and set an “overweight” rating on the stock in a research note on Thursday. Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $90.00 price target on shares of Acadia Healthcare in a report on Tuesday, March 5th. Royal Bank of Canada restated an “outperform” rating and issued a $94.00 price objective on shares of Acadia Healthcare in a research report on Monday, March 4th. Finally, Deutsche Bank Aktiengesellschaft raised shares of Acadia Healthcare from a “sell” rating to a “hold” rating and set a $70.00 price target on the stock in a research note on Thursday, April 25th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $88.89.

Acadia Healthcare Trading Down 0.9 %

Shares of ACHC opened at $66.12 on Friday. The stock has a 50 day simple moving average of $76.77 and a 200-day simple moving average of $77.52. The company has a current ratio of 1.27, a quick ratio of 0.67 and a debt-to-equity ratio of 0.63. The stock has a market cap of $6.11 billion, a PE ratio of -472.25, a PEG ratio of 1.97 and a beta of 1.31. Acadia Healthcare has a 1 year low of $64.74 and a 1 year high of $87.77.

Acadia Healthcare (NASDAQ:ACHC) last issued its earnings results on Wednesday, May 1st. The company reported $0.84 EPS for the quarter, beating the consensus estimate of $0.80 by $0.04. The company had revenue of $768.10 million for the quarter, compared to the consensus estimate of $779.20 million. Acadia Healthcare had a negative net margin of 0.38% and a positive return on equity of 11.49%. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.75 EPS. On average, sell-side analysts predict that Acadia Healthcare will post 3.56 EPS for the current fiscal year.

Insider Buying and Selling at Acadia Healthcare

In other news, Director Wade D. Miquelon sold 2,203 shares of the firm’s stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $85.39, for a total value of $188,114.17. Following the transaction, the director now directly owns 46,074 shares in the company, valued at approximately $3,934,258.86. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Headlands Technologies LLC bought a new position in shares of Acadia Healthcare during the third quarter worth $25,000. GAMMA Investing LLC bought a new position in shares of Acadia Healthcare during the 4th quarter valued at about $26,000. Mather Group LLC. bought a new stake in Acadia Healthcare during the 1st quarter worth approximately $48,000. Fifth Third Bancorp lifted its stake in Acadia Healthcare by 25.5% in the fourth quarter. Fifth Third Bancorp now owns 670 shares of the company’s stock valued at $52,000 after buying an additional 136 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale acquired a new position in shares of Acadia Healthcare in the third quarter valued at approximately $96,000.

Acadia Healthcare Company Profile

Acadia Healthcare Company, Inc provides behavioral healthcare services in the United States and Puerto Rico. The company develops and operates acute inpatient psychiatric facilities, specialty treatment facilities comprising residential recovery facilities and eating disorder facilities, comprehensive treatment centers, and residential treatment centers, as well as facilities offering outpatient behavioral healthcare services for the behavioral healthcare and recovery needs of communities.